# Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

> **NCT01392326** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 606 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Secukinumab (75 mg)
- **DRUG:** Secukinumab (150 mg)
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT01392326
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392326, "Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01392326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*